Please assess the completion status of the following clinical trial:

Trial Title: Effect of Bradykinin Receptor Antagonism on ACE Inhibitor-associated Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has ongoing angioedema while taking an ACE inhibitor.~* The subject is between 18 and 80 years of age.~Exclusion Criteria:~* The subject has had angioedema while not taking an ACE inhibitor.~* The subject's angioedema only involves the bowel.~* The subject is known to be pregnant or has a positive urine pregnancy test.~* The subject has started on an oral contraceptive within the last 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- icatibant (Type: EXPERIMENTAL): 30 mg icatibant will be administered subcutaneously 0 and 6 hours after randomization
- Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous at time 0 and 6 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).